Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders.
To identify patients with medullary thyroid carcinoma (MTC) at a potentially curable stage of the disease, serum concentrations of calcitonin (hCT) were determined in 14,000 patients (including 10,158 patients with thyroid nodules) referred to a thyroid outpatient clinic. Excluding patients in whom elevated basal hCT concentrations had already been known at the time of their referral, 507 patients with thyroid nodules presented basal concentrations of hCT of more than 10 pg/ml. Following stimulation by IV pentagastrin (0.5 microg/kg BW), hCT concentrations of more than 100 pg/ml were seen in 103 patients. This group included 32 new cases of MTC (29 patients with sporadic MTC and 3 new index cases of the familial form) and 43 patients with C cell hyperplasia (CCH). Among the 3,843 patients without thyroid nodules, 2 were found to harbor sporadic MTC while 4 had CCH. As compared to 1.1 cases of MTC per 1,000 patients with nodular thyroid diseases diagnosed in our institution before hCT screening was begun, 3.2 cases of MTC per 1,000 patients were identified when hCT was determined in all patients with thyroid nodules. The determination of hCT in all patients with thyroid nodular disease facilitates the timely diagnosis of MTC, thus providing the chance of curative surgery.
Vierhapper
H
H
Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Austria. heinrich.vierhapper@meduniwien.ac.at
Niederle
B
B
Bieglmayer
C
C
Kaserer
K
K
Baumgartner-Parzer
S
S
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002116:Calcitonin / Q000097:blood*; D018276:Carcinoma, Medullary / Q000175:diagnosis* / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010418:Pentagastrin; D011518:Proto-Oncogene Proteins / Q000235:genetics / Q000378:metabolism; D013959:Thyroid Diseases / Q000150:complications* / Q000628:therapy*; D013964:Thyroid Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D016606:Thyroid Nodule / Q000150:complications / Q000473:pathology / Q000628:therapy
D011518:Proto-Oncogene Proteins; D002116:Calcitonin; D010418:Pentagastrin